HEMATOPOIETIC CELL EXPANSION SYSTEM

Information

  • Research Project
  • 2016565
  • ApplicationId
    2016565
  • Core Project Number
    R44DK045558
  • Full Project Number
    5R44DK045558-03
  • Serial Number
    45558
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/1993 - 31 years ago
  • Project End Date
    11/30/1998 - 26 years ago
  • Program Officer Name
    BADMAN, DAVID G.
  • Budget Start Date
    9/25/1996 - 28 years ago
  • Budget End Date
    11/30/1998 - 26 years ago
  • Fiscal Year
    1996
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/27/1996 - 28 years ago
Organizations

HEMATOPOIETIC CELL EXPANSION SYSTEM

DESCRIPTION: (Adapted from the Applicant's Abstract) Bone marrow and stem cell transplantation is being used for an increasing number of procedures that are performed on patients undergoing chemo- or radiotherapy. This procedure can be simplified, made more cost effective and reliable if hematopoietic stem, progenitor and precursor cells could be expanded greatly in number from a small aspirate. During Phase I of this program, a prototype perfusion bioreactor system was developed that enables the expansion of bone marrow cells from adult donors as well as hematopoietic cells obtained from mobilized peripheral blood and umbilical cord blood. Bone marrow cell populations expand by a factor of 8 and 10 while their progenitor cell content increased by a factor of 10 to 30 and the number of long- term culture initiating cells increased by 4 to 10 fold. The objectives of the proposed Phase II program are: 1. Define the material composition and characteristics of the cell growth surfaces, and techniques for large volume manufacturing; 2. Optimize oxygen delivery and other operating conditions necessary for the production of human stem and hematopoietic progenitor cells using cell culture chambers; 3. Design, build and test a clinical size unit based on the parameters defined using the small scale units; and 4. Evaluate cell growth reliability of the cell culture chambers and define the expansion characteristics of patient and normal donor marrow in this system. Successful completion of this program will lead to clinical trials to determine the efficacy of expanded hematopoietic cell populations.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    HEM
  • Study Section Name
    Hematology Subcommittee 2
  • Organization Name
    AASTROM BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48105
  • Organization District
    UNITED STATES